Vaccitech reemerges as Barinthus with hep B data showing declines in infection levels

Barinthus Biotherapeutics, recently renamed from Vaccitech, is ready to showcase its new direction. The biotech revealed some early data from a pair of trials of its hepatitis B virus therapy, showing declines in levels of infection.